HOME >> BIOLOGY >> NEWS
Cellular espionage at play in post-menopausal osteoporosis

Bone researchers have long known that post-menopausal women are at increased risk of bone loss and diseases such as osteoporosis because of low levels of the hormone estrogen. In recent years, estrogen replacement therapy has been the course of action to prevent bone loss in such women. But not all women are acceptable candidates for this therapy because some may be predisposed to breast, uterine and ovarian cancer risks if they take increased estrogen.

Despite advances in estrogen replacement therapy, it is a source of hot debate in the biomedical community over what cell, molecular and biochemical processes are involved in bone loss associated with declining estrogen levels.

Now a group of biologists at Washington University in St. Louis has shown that lower estrogen levels in post-menopausal women allow a class of inflammatory molecules called cytokines to bind to bone cell surfaces. This in turn gives the green light for specialized cells called osteoclasts to perform their specialty -- bone resorption, or destruction. Moreover, the Washington University team headed by Philip Osdoby, Ph.D., professor of biology in Arts and Sciences, and Teresa Sunyer, Ph.D., research assistant professor of biology, has shown a new relationship between estrogen, bone cell surface receptor proteins and the cytokines Interleukin 1 (IL-1) and Interleukin 8 (IL-8).

Their findings reveal a "cellular espionage" scenario involving signaling receptor proteins and decoy receptor proteins. Osdoby, Sunyer and colleagues found that, in the presence of estrogen, decoy receptor proteins increase in bone cells, preventing cytokines from initiating the path of bone destruction. Without estrogen, signaling receptor proteins flourish and the decoys diminish, letting the osteoclasts erode bone.

The results were published in the May 15, 1999, issue of the Journal of Clinical Investigation. The research was supported by grants from the National Institutes of Health.

B
'"/>

Contact: Tony Fitzpatrick
tony_fitzpatrick@aismail.wustl.edu
314-935-5272
Washington University in St. Louis
26-Jul-1999


Page: 1 2 3 4

Related biology news :

1. Cellular problems found behind complex obesity syndrome
2. Cellular fat sensor slows heart disease
3. Cellular problem discovered behind syndrome of obesity, learning disabilities
4. Clock cues: Cellular sensing, metabolism research wins Amersham Biosciences and Science Prize
5. Cellular pathway includes a clock that steers gene activity
6. Cellular organelle evolved repeatedly
7. Cellular membrane changes associated with acclimation to cold
8. Dual Control Strategy Assures Accurate Cellular Marching Orders, But A Pathogenic Microbe Can Hijack The System
9. UC Davis Researchers Get First Look At A Working Cellular Motor
10. Cellular Target Of Leprosy, Deadly Viruses Found
11. New Insights On Sequence of Cell Death After Brain Injury: Understanding Cellular Events After Brain Trauma Could Lead To Better Therapies

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Cellular espionage play post menopausal osteoporosis

(Date:10/15/2014)... is a non-traditional biophysics textbook and it describes how ... journey of discovery into biological systems and provides an ... It is about how our genes make proteins that ... of cells in an organism. It quantifies the principles ... can be found on both large and small scales. ...
(Date:10/15/2014)... Alt will be awarded the 44th Rosenstiel Award for ... his pioneering research exploring the mechanisms of genomic instability ... cells. Alt is the second alumnus to win the ... Prize in 2003. , Alt is the Charles A. ... Harvard Medical School and an investigator at the Howard ...
(Date:10/14/2014)... N.Y. – Scientists have sequenced the house fly genome ... one might expect from an insect that thrives in ... published Oct. 14 in the journal Genome Biology ... biology and of how flies quickly adapt to resist ... Adult house flies (Musca domestica) carry and transmit more ...
Breaking Biology News(10 mins):New book about life as seen from physics 2Brandeis awards 44th Rosenstiel Award to pioneering geneticist Fred Alt 2House fly genome reveals expanded immune system 2
(Date:10/22/2014)... , Oct. 22, 2014   Synthetic Biologics, ... novel pathogen-specific therapies for serious infections and diseases, announced ... issued a Notice of Allowance for a composition of ... C. difficile program, SYN-004. This is Synthetic ... in the U.S. and adds to the Company,s extensive ...
(Date:10/22/2014)... SAN DIEGO and HONG KONG ... an innovative rare disease therapeutics enterprise, announced today that ... joined the company as vice president, research. Dr. McKew ... research, including key leadership positions at the National Institutes ... to its acquisition by Wyeth). Dr. McKew will lead aTyr,s ...
(Date:10/20/2014)... 2014 Asterias Biotherapeutics, Inc. (NYSE MKT: ... a Notice of Grant Award (NGA) with the ... 1, 2014.  The NGA provides for the immediate ... of additional grant funds pursuant to the previously ... development of Asterias, product, AST-OPC1. The grant provides ...
(Date:10/20/2014)... , Oct. 20, 2014 PureTech ... company tackling big healthcare problems, announced today the ... round, with participation from Invesco Perpetual, a $120 ... used to drive PureTech,s existing pipeline forward and ... "PureTech has the scientific creativity to really go ...
Breaking Biology Technology:Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 2Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 4aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 4PureTech Announces Expansion with Oversubscribed $55M Funding Round 2PureTech Announces Expansion with Oversubscribed $55M Funding Round 3PureTech Announces Expansion with Oversubscribed $55M Funding Round 4PureTech Announces Expansion with Oversubscribed $55M Funding Round 5PureTech Announces Expansion with Oversubscribed $55M Funding Round 6
Cached News: